We are live on ! Find out more
RDHL

Redhill Biopharma
RDHL

22 hedge funds and large institutions have $21.2M invested in Redhill Biopharma in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

5% more funds holding

Funds holding: 21 → 22 (+1)

31% less capital invested

Capital invested by funds: $30.5M → $21.2M (-$9.32M)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ISL
Ingalls & Snyder LLC
New York
+$486K
2
OC
Oppenheimer & Co
New York
+$150K
3
TRCT
Tower Research Capital (TRC)
New York
+$11.6K
4
VanEck Associates
VanEck Associates
New York
+$11.6K

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$6.13M
2
BC
Broadfin Capital
New York
-$937K
3
SM
Sabby Management
Florida
-$104K
4
Morgan Stanley
Morgan Stanley
New York
-$57.8K
5
Deutsche Bank
Deutsche Bank
Germany
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$8.01M -$937K -81 -10%
O
2
OrbiMed
New York
$6.14M – – –
MMH
3
Menora Mivtachim Holdings
Israel
$2.67M – – –
SM
4
Sabby Management
Florida
$1.61M -$104K -9 -6%
CS
5
Candriam SCA
Luxembourg
$778K – – –
BHB
6
Bank Hapoalim BM
Israel
$498K – – –
ISL
7
Ingalls & Snyder LLC
New York
$451K +$486K +42 New
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$228K – – –
FM
9
Family Management
New York
$179K – – –
FAM
10
Fred Alger Management
New York
$169K – – –
OC
11
Oppenheimer & Co
New York
$142K +$150K +13 New
VanEck Associates
12
VanEck Associates
New York
$105K +$11.6K +1 +11%
PVH
13
Psagot Value Holdings
Israel
$51K -$11.6K -1 -17%
Wells Fargo
14
Wells Fargo
California
$33K -$11.6K -1 -25%
MMG
15
Monetary Management Group
Missouri
$33K – – –
UBS Group
16
UBS Group
Switzerland
$22K – – –
AIM
17
Acrospire Investment Management
Illinois
$12K – – –
Morgan Stanley
18
Morgan Stanley
New York
$11K -$57.8K -5 -83%
Bank of America
19
Bank of America
North Carolina
$11K – – –
Creative Planning
20
Creative Planning
Kansas
$11K – – –
WA
21
WFG Advisors
Texas
$8K – – –
TRCT
22
Tower Research Capital (TRC)
New York
$7K +$11.6K +1 New
TWA
23
TCI Wealth Advisors
Arizona
$4K – – –
VAM
24
Visium Asset Management
New York
– -$6.13M -500 Closed
Deutsche Bank
25
Deutsche Bank
Germany
– -$11.6K -1 Closed

RDHL Hedge Fund Activity: Q2 2016 in Review

22 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2016, worth a combined $21.2M — down 31% from $30.5M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new RDHL positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 5 trimmed.

The largest buyer was Ingalls & Snyder LLC, opening a new position worth an estimated $486K. The largest seller was Visium Asset Management, exiting entirely with an estimated $6.13M sold.

  • 22 institutional investors held Redhill Biopharma (RDHL) as of Q2 2016, up from 21 in Q1 2016.
  • Funds reported $21.2M of Redhill Biopharma stock for Q2 2016, down 31% quarter-over-quarter.
  • 3 funds opened new Redhill Biopharma positions in Q2 2016 and 2 closed out, a net change of +1 holder.
  • The largest Redhill Biopharma buyer in Q2 2016 was Ingalls & Snyder LLC, an estimated $486K added.
  • The largest Redhill Biopharma seller in Q2 2016 was Visium Asset Management, an estimated $6.13M sold.

Based on aggregated 13F filings for Q2 2016.